Gut health and overall well-being Digestive System
Conditions
Interventions
Volunteers (F/M balanced, young adults aged 18-35 years, n = 15/treatment group) will consume either spray dried fucoidan (250 mg in vegan clear capsules )or placebo (microcrystalline cellulose) contr
Sponsors
Aberystwyth University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Consenting adults aged 18 -35 years 2. Able to provide written informed consent PRIOR to performing any study procedures 3. Are able to commit to consuming daily supplements 4. Willing to complete a series of online questionnaires
Exclusion criteria
Exclusion criteria: 1. Serious health conditions that require daily long-term medications 2. Allergens: any participant with molluscs and crustacean allergens 3. Those taking anticoagulant and blood sugar-lowering medications 4. A history of or current diabetes or gut inflammation (Crohn's, IBD) 5. Subjects with a medical condition or disease that is life-threatening 6. Consume a high dose of alcohol >21 units per week for men and >14 units per week for women 7. Food allergy/food intolerance/ eating disorder or are on a specially prescribed diet 8. Pregnant or breastfeeding 9. Subjects who smoke cigarettes or use other products containing nicotine 10. Subjects who are already regularly taking fucoidan or supplements related to fucoidan within 30 days of screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Gastrointestinal health measured using Digestion-Associated Quality of Life Questionnaire (DQLQ) and Bristol Stool Scale/Bristol Stool Chart from baseline to 28 days post-intervention 2. General health and well-being measured using Short Form Health Survey (SF-12), General Health Questionnaire (GHQ-12), EQ-5D items (Health Survey for England) from baseline to 28 days post-intervention 3. Mental well-being measured using Warwick-Edinburgh Mental Well-being Scale (WEMWBS) from baseline to 28 days post-intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Feasibility of fucoidan supplementation measured using participant compliance (daily intake tracking) and completion rates of online questionnaires and diet diaries across 28 days of intervention 2. Dietary patterns and food intake measured using online diet diaries via Intake24 from baseline to 28 days post-intervention 3. Variability in response to fucoidan measured using inter-individual variation in questionnaire outcomes (GI symptoms, mental well-being, general health) from baseline to 28 days post-intervention | — |
Countries
United Kingdom, Wales
Contacts
Public ContactAmanda Jane Lloyd
Outcome results
None listed